{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:12:22Z","timestamp":1761747142783,"version":"build-2065373602"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sanofi (China) Investment Co., Ltd","award":["Sanofi (China) Investment Co., Ltd"],"award-info":[{"award-number":["Sanofi (China) Investment Co., Ltd"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disorder caused by deficiency of the enzyme \u03b1-L-iduronidase. Laronidase (Aldurazyme\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) stands as the sole FDA-approved enzyme replacement therapy (ERT) for MPS I to date. In June 2020, a concentrated solution of laronidase for injection received approval for a Chinese bioproduct license, exempted from clinical trials. Compliance with approval requirements mandates post-marketing surveillance (PMS) for laronidase. The objective of this study was to evaluate the safety and efficacy of laronidase treatment at a dosage of 100 U\/kg body weight weekly in Chinese patients with MPS I.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From October 2021 to July 2023, 12 MPS I patients at four institutions in China received weekly intravenous injections of laronidase at a dose of 100 U\/kg of body weight once a week for 26 weeks. The primary efficacy endpoint was the percentage change in urinary glycosaminoglycans (uGAGs) levels at week 26 relative to baseline. Safety endpoints included the incidence of adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs, including infusion-related reactions) during the treatment period (TE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Laronidase consistently reduced uGAGs levels from baseline to week 26, with a percentage change of -64.61%\u2009\u00b1\u200926.90% (95% CI: -81.70% to -47.52%). There was a revealed reduction following laronidase treatment. The percentage reductions in uGAGs from baseline to weeks 2, 4, 8, 12, and 20 were decreased. The decreases in absolute change of uGAGs were observed at weeks 2, 4, 8, 12, 20, and 26. The percentage reduction in liver volume from baseline to week 26 was \u2212\u200913.24%\u2009\u00b1\u20097.86% (95% CI: -18.24% to -8.25%). Nine participants (75%) achieved an overall treatment compliance rate\u2009\u226580%. Eleven participants (91.7%) experienced treatment-emergent adverse events (TEAEs). Four participants (33.3%) experienced AESIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In Chinese patients with MPS I, laronidase as an enzyme replacement therapy effectively reduces glycosaminoglycan storage and liver volume while demonstrating a favorable safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration number<\/jats:title>\n                    <jats:p>NCT05134571.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration date<\/jats:title>\n                    <jats:p>2021-10-21.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Name of the registry<\/jats:title>\n                    <jats:p>\n                      China Post-marketing Surveillance (PMS) Study of Aldurazyme\n                      <jats:sup>\u00ae<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>URL of the trial registry record<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/search?term=NCT05134571\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/search?term=NCT05134571<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-04056-w","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:58:33Z","timestamp":1761739113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of laronidase in Chinese patients with mucopolysaccharidosis type I: a phase IV, single-arm, open-label, multicenter study"],"prefix":"10.1186","volume":"20","author":[{"given":"Yan","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Chun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Ping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"4056_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13023-019-1027-3","volume":"14","author":"T Conner","year":"2019","unstructured":"Conner T, Cook F, Fernandez V, Rascati K, Rangel-Miller V. An online survey on burden of illness among families with post-stem cell transplant mucopolysaccharidosis type I children in the United States. Orphanet J Rare Dis. 2019;14:48.","journal-title":"Orphanet J Rare Dis"},{"key":"4056_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1750-1172-6-55","volume":"6","author":"MH de Ru","year":"2011","unstructured":"de Ru MH, Boelens JJ, Das AM, Jones SA, van der Lee JH, Mahlaoui N, et al. Enzyme replacement therapy and\/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis. 2011;6:55.","journal-title":"Orphanet J Rare Dis"},{"key":"4056_CR3","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","volume":"121","author":"SA Khan","year":"2017","unstructured":"Khan SA, Peracha H, Ballhausen D, Wiesbauer A, Rohrbach M, Gautschi M, Mason RW, Giugliani R, Suzuki Y, Orii KE, Orii T, Tomatsu S. Epidemiology of mucopolysaccharidoses. Mol Genet Metab. 2017;121:227\u201340.","journal-title":"Mol Genet Metab"},{"key":"4056_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/jhg.2015.155","volume":"61","author":"X Chen","year":"2016","unstructured":"Chen X, Qiu W, Ye J, Han L, Gu X, Zhang H. Demographic characteristics and distribution of lysosomal storage disorder subtypes in Eastern China. J Hum Genet. 2016;61:345\u20139.","journal-title":"J Hum Genet"},{"key":"4056_CR5","first-page":"1537","volume":"33","author":"X Zhao","year":"2018","unstructured":"Zhao X, Huang Y, Sheng H, Lin Y, Li X, Su X, Feng Y, Cai Y, Liu L. High risk screening and disease spectrum for 24 kinds of lysosomal storage diseases. Chin J Appl Clin Pediatr. 2018;33:1537\u201340.","journal-title":"Chin J Appl Clin Pediatr"},{"key":"4056_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1542\/peds.2008-0416","volume":"123","author":"J Muenzer","year":"2009","unstructured":"Muenzer J, Wraith JE, Clarke LA. International consensus panel on management and treatment of mucopolysaccharidosis I. mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. 2009;123:19\u201329.","journal-title":"Pediatrics"},{"key":"4056_CR7","unstructured":"Clarke LA, Mucopolysaccharidosis type I. 2002 Oct 31 [Updated 2021 Feb 25]. In: Adam MP, Feldman J, Mirzaa GM, editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993\u20132023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1162\/."},{"key":"4056_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1517\/14656566.6.3.489","volume":"6","author":"JE Wraith","year":"2005","unstructured":"Wraith JE. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother. 2005;6:489\u2013506.","journal-title":"Expert Opin Pharmacother"},{"key":"4056_CR9","first-page":"CD009354","volume":"6","author":"E Jameson","year":"2019","unstructured":"Jameson E, Jones S, Remmington T. Enzyme replacement therapy with laronidase (Aldurazyme\u00ae) for treating mucopolysaccharidosis type I. Cochrane Database Syst Rev. 2019;6:CD009354.","journal-title":"Cochrane Database Syst Rev"},{"key":"4056_CR10","first-page":"100736","volume":"27","author":"A Wilson","year":"2021","unstructured":"Wilson A, Colzani RM, Flores AL. Real-world data assessment of safety of home-based and hospital\/outpatient-based laronidase enzyme replacement therapy for mucopolysaccharidosis I. Mol Genet Metab Rep. 2021;27:100736.","journal-title":"Mol Genet Metab Rep"},{"key":"4056_CR11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","volume":"144","author":"JE Wraith","year":"2004","unstructured":"Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr. 2004;144:581\u20138.","journal-title":"J Pediatr"},{"key":"4056_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1542\/peds.2007-3847","volume":"123","author":"LA Clarke","year":"2009","unstructured":"Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Sidman M, Kakkis ED, Cox GF. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009;123:229\u201340.","journal-title":"Pediatrics"},{"key":"4056_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jpeds.2016.08.033","volume":"178","author":"S Laraway","year":"2016","unstructured":"Laraway S, Mercer J, Jameson E, Ashworth J, Hensman P, Jones SA. Outcomes of long-term treatment with laronidase in patients with mucopolysaccharidosis type I. J Pediatr. 2016;178:219\u201326.","journal-title":"J Pediatr"},{"key":"4056_CR14","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1542\/peds.2006-2156","volume":"120","author":"JE Wraith","year":"2007","unstructured":"Wraith JE, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y, Kakkis ED, Guffon N. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of Recombinant human alpha-L-iduronidase (laronidase). Pediatrics. 2007;120:e37\u201346.","journal-title":"Pediatrics"},{"key":"4056_CR15","unstructured":"Prescribing Information of Aldurazyme\u00ae (laronidase) injection, for intravenous use. Initial U.S. Approval. 2003. Revised: 03\/2023."},{"key":"4056_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12881-016-0284-4","volume":"17","author":"O Gabrielli","year":"2016","unstructured":"Gabrielli O, Clarke LA, Ficcadenti A, Santoro L, Zampini L, Volpi N, Coppa GV. 12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment. BMC Med Genet. 2016;17:19.","journal-title":"BMC Med Genet"},{"key":"4056_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13023-015-0344-4","volume":"10","author":"NA Al-Sannaa","year":"2015","unstructured":"Al-Sannaa NA, Bay L, Barbouth DS, Benhayoun Y, Goizet C, Guelbert N, et al. Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships. Orphanet J Rare Dis. 2015;10:131.","journal-title":"Orphanet J Rare Dis"},{"key":"4056_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ymgme.2013.04.023","volume":"109","author":"S Laraway","year":"2013","unstructured":"Laraway S, Breen C, Mercer J, Jones S, Wraith JE. Does early use of enzyme replacement therapy alter the natural history of mucopolysaccharidosis I? Experience in three siblings. Mol Genet Metab. 2013;109:315\u20136.","journal-title":"Mol Genet Metab"},{"key":"4056_CR19","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1007\/s10545-007-0613-z","volume":"30","author":"A Hirth","year":"2007","unstructured":"Hirth A, Berg A, Greve G. Successful treatment of severe heart failure in an infant with hurler syndrome. J Inherit Metab Dis. 2007;30:820.","journal-title":"J Inherit Metab Dis"},{"key":"4056_CR20","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1007\/s10545-006-0329-5","volume":"29","author":"RL Soutar","year":"2006","unstructured":"Soutar RL, Mercer J, Wraith JE. Impact of 144 weeks of laronidase therapy on body functions, endurance and general well-being in a Hurler-Scheie patient. J Inherit Metab Dis. 2006;29:590.","journal-title":"J Inherit Metab Dis"},{"key":"4056_CR21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.pedneo.2019.05.005","volume":"60","author":"HY Lin","year":"2019","unstructured":"Lin HY, Lee CL, Chuang CK, Lin SP. Long-term outcomes of enzyme replacement therapy for Taiwanese patients with mucopolysaccharidosis I. Pediatr Neonatol. 2019;60:577\u20138.","journal-title":"Pediatr Neonatol"},{"key":"4056_CR22","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1016\/j.bbmt.2016.08.015","volume":"22","author":"J Wang","year":"2016","unstructured":"Wang J, Luan Z, Jiang H, Fang J, Qin M, Lee V, Chen J. Allogeneic hematopoietic stem cell transplantation in thirty-four pediatric cases of Mucopolysaccharidosis-a ten-year report from the China children transplant group. Biol Blood Marrow Transpl. 2016;22:2104\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"key":"4056_CR23","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/gim.2018.29","volume":"20","author":"JB Eisengart","year":"2018","unstructured":"Eisengart JB, Rudser KD, Xue Y, Orchard P, Miller W, Lund T, et al. Long-term outcomes of systemic therapies for hurler syndrome: an international multicenter comparison. Genet Med. 2018;20:1423\u20139.","journal-title":"Genet Med"},{"key":"4056_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13023-020-01644-w","volume":"16","author":"N Guffon","year":"2021","unstructured":"Guffon N, Pettazzoni M, Pangaud N, Garin C, Lina-Granade G, Plault C, et al. Long term disease burden post-transplantation: three decades of observations in 25 hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT). Orphanet J Rare Dis. 2021;16:60.","journal-title":"Orphanet J Rare Dis"},{"key":"4056_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/01.GIM.0000154299.22120.6A","volume":"7","author":"SS Grewal","year":"2005","unstructured":"Grewal SS, Wynn R, Abdenur JE, Burton BK, Gharib M, Haase C, et al. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in hurler syndrome. Genet Med. 2005;7:143\u20136.","journal-title":"Genet Med"},{"key":"4056_CR26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ymgme.2016.01.011","volume":"117","author":"A Ghosh","year":"2016","unstructured":"Ghosh A, Miller W, Orchard PJ, Jones SA, Mercer J, Church HJ, Tylee K, Lund T, Bigger BW, Tolar J, Wynn RF. Enzyme replacement therapy prior to Haematopoietic stem cell transplantation in mucopolysaccharidosis type I: 10 year combined experience of 2 centres. Mol Genet Metab. 2016;117:373\u20137.","journal-title":"Mol Genet Metab"},{"key":"4056_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10545-012-9500-3","volume":"36","author":"DH Wiseman","year":"2013","unstructured":"Wiseman DH, Mercer J, Tylee K, Malaiya N, Bonney DK, Jones SA, Wraith JE, Wynn RF. Management of mucopolysaccharidosis type IH (Hurler\u2019s syndrome) presenting in infancy with severe dilated cardiomyopathy: a single institution\u2019s experience. J Inherit Metab Dis. 2013;36:263\u201370.","journal-title":"J Inherit Metab Dis"},{"key":"4056_CR28","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/sj.bmt.1705934","volume":"41","author":"J Tolar","year":"2008","unstructured":"Tolar J, Grewal SS, Bjoraker KJ, Whitley CB, Shapiro EG, Charnas L, Orchard PJ. Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for hurler syndrome. Bone Marrow Transpl. 2008;41:531\u20135.","journal-title":"Bone Marrow Transpl"},{"key":"4056_CR29","doi-asserted-by":"publisher","first-page":"14105","DOI":"10.1038\/s41598-019-50595-1","volume":"9","author":"TC Lund","year":"2019","unstructured":"Lund TC, Miller WP, Liao AY, Tolar J, Shanley R, Pasquali M, Sando N, Bigger BW, Polgreen LE, Orchard PJ. Post-transplant laronidase augmentation for children with hurler syndrome: biochemical outcomes. Sci Rep. 2019;9:14105.","journal-title":"Sci Rep"},{"key":"4056_CR30","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jpeds.2012.07.052","volume":"162","author":"JB Eisengart","year":"2013","unstructured":"Eisengart JB, Rudser KD, Tolar J, Orchard PJ, Kivisto T, Ziegler RS, Whitley CB, Shapiro EG. Enzyme replacement is associated with better cognitive outcomes after transplant in hurler syndrome. J Pediatr. 2013;162:375\u201380.","journal-title":"J Pediatr"},{"issue":"1","key":"4056_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41390-019-0541-2","volume":"87","author":"LE Polgreen","year":"2020","unstructured":"Polgreen LE, Lund TC, Braunlin E, Tolar J, Miller BS, Fung E, Whitley CB, Eisengart JB, Northrop E, Rudser K, Miller WP, Orchard PJ. Clinical trial of laronidase in hurler syndrome after hematopoietic cell transplantation. Pediatr Res. 2020;87(1):104\u201311.","journal-title":"Pediatr Res"},{"key":"4056_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10545-016-0006-2","volume":"40","author":"NJ Rodgers","year":"2017","unstructured":"Rodgers NJ, Kaizer AM, Miller WP, Rudser KD, Orchard PJ, Braunlin EA. Mortality after hematopoietic stem cell transplantation for severe mucopolysaccharidosis type I: the 30-year university of Minnesota experience. J Inherit Metab Dis. 2017;40:271\u201380.","journal-title":"J Inherit Metab Dis"},{"key":"4056_CR33","first-page":"88","volume":"3","author":"L Arranz","year":"2015","unstructured":"Arranz L, Aldamiz-Echevarria L. Enzyme replacement therapy in hurler syndrome after failure of hematopoietic transplant. Mol Genet Metab Rep. 2015;3:88\u201391.","journal-title":"Mol Genet Metab Rep"},{"key":"4056_CR34","first-page":"72","volume":"20","author":"Y Zou","year":"2022","unstructured":"Zou Y, Lian D, Sun J, Ma M. Enzyme replacement therapy in child with mucopolysaccharidoses I: a case report. Clin Med J. 2022;20:72\u20134.","journal-title":"Clin Med J"},{"key":"4056_CR35","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.braindev.2019.01.008","volume":"41","author":"N Yamazaki","year":"2019","unstructured":"Yamazaki N, Kosuga M, Kida K, Takei G, Fukuhara Y, Matsumoto H, Senda M, Honda A, Ishiguro A, Koike T, Yabe H, Okuyama T. Early enzyme replacement therapy enables a successful hematopoietic stem cell transplantation in mucopolysaccharidosis type IH: divergent clinical outcomes in two Japanese siblings. Brain Dev. 2019;41:546\u201350.","journal-title":"Brain Dev"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04056-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-04056-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-04056-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:58:36Z","timestamp":1761739116000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-04056-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4056"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-04056-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out in compliance with the Declaration of Helsinki. This study was approved by the Clinical Trial Ethics Committee of Huazhong University of Science and Technology (2021\u2009\u2212\u2009118), the Drug Clinical Trial Ethics Committee of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (002603), the Biomedical Research Ethics Committee of Peking University First Hospital (2021-088), the Drug\/Medical Device Clinical Trial Ethics Committee of Guangzhou Women and Children\u2019s Medical Center (YW-202109) and the Medical Ethics Committee of Children\u2019s Hospital of Zhejiang University School of Medicine. Written informed consent was obtained from all the participants for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The work described has not been submitted elsewhere for publication, in whole or in part, and all the authors listed have approved the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YJ and XL are Sanofi employees, YW is Sanofi former employee and Hengrui Pharma current employee. YW and XL hold stocks of Sanofi (China) Investment Co., Ltd. There are no potential conflicts of interest to disclose from YL, YLY, CCZ, LL, and XPL.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"547"}}